Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,025 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01693783 | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Nov 8, 2022 | clinicaltrials |
| NCT03660449 | Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT03502148 | Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma(PRV111) | completed | Phase 1 / Phase 2 | 10 | Privo TechnologiesINDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT02218164 | Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT00446446 | PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) | completed | Phase 2 | 52 | AmgenINDUSTRY | 0 | Oct 5, 2022 | clinicaltrials |
| NCT01458392 | Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 46 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02849743 | Intranasal Oxytocin in Hypothalamic Obesity | completed | Phase 2 | 18 | Shana McCormack, MDOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02002182 | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | completed | Phase 2 | 15 | Andrew SikoraOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT01592721 | Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 6 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | completed | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT02268695 | Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC(TPExtreme) | completed | Phase 2 | 541 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 3 | Aug 23, 2022 | clinicaltrials |
| NCT01864772 | Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC(ELANFIT) | completed | Phase 2 | 85 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT03925870 | KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 45 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT03057613 | The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 18 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02255097 | Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) | completed | Phase 2 | 172 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 28, 2022 | clinicaltrials |
| NCT02920476 | TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) | completed | Phase 2 | 4 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT04293679 | Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC | completed | Phase 1 / Phase 2 | 25 | SirnaomicsINDUSTRY | 1 | Jun 9, 2022 | clinicaltrials |
| NCT01884259 | Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN(HNO-2) | completed | Phase 2 | 100 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02417701 | Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03292250 | Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] | completed | Phase 2 | 180 | Seoul National University HospitalOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT03067610 | Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer(INFIELD) | completed | Phase 2 | 72 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT03330249 | Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion(CisFRad) | completed | Phase 2 | 124 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02684253 | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | completed | Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02873819 | Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity | completed | Phase 2 | 80 | Gliknik Inc.INDUSTRY | 7 | Mar 8, 2022 | clinicaltrials |
| NCT01104922 | Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 48 | David A. Clump, MD, PhDOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01332266 | E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 95 | Eisai Inc.INDUSTRY | 4 | Jan 3, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT03430895 | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | completed | Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT00660218 | A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer | completed | Phase 1 / Phase 2 | 53 | State University of New York - Upstate Medical UniversityOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | completed | Phase 2 | 5 | Seagen Inc.INDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT03574753 | Lung-MAP S1400K: c-MET Positive | completed | Phase 2 | 28 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 18, 2021 | clinicaltrials |
| NCT01816984 | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03377556 | Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer | completed | Phase 2 | 51 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 23, 2021 | clinicaltrials |
| NCT02785939 | Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | completed | Phase 2 / Phase 3 | 53 | SWOG Cancer Research NetworkNETWORK | 1 | May 27, 2021 | clinicaltrials |
| NCT02965378 | Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | completed | Phase 2 / Phase 3 | 43 | SWOG Cancer Research NetworkNETWORK | 2 | May 27, 2021 | clinicaltrials |
| NCT01728233 | Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis(HER-Uro01) | completed | Phase 2 | 32 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT02762513 | Expansion Trial for Axitinib In Head And Neck Cancer | completed | Phase 2 | 29 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT01077999 | Chemoradiation and Panitumumab for Esophageal Cancer | completed | Phase 2 | 78 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02394652 | The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT03194373 | Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 21 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT00896181 | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 26 | Stanford UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT00084682 | Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2021 | clinicaltrials |
| NCT03116152 | Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment | completed | Phase 2 | 190 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04225364 | Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 56 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT01414426 | Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions | completed | Phase 2 | 20 | University of ChicagoOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT02883556 | Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin(CARSKIN) | completed | Phase 2 | 57 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT00210470 | A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer | completed | Phase 2 | 27 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 0 | Dec 11, 2020 | clinicaltrials |
| NCT01689194 | Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer | completed | Phase 2 | 53 | Seoul National University HospitalOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01386632 | Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma | completed | Phase 2 | 50 | Sanford HealthOTHER | 1 | Oct 27, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Nov 8, 2022source: clinicaltrials